ProQR Therapeutics N.V. - Ordinary Shares (PRQR) News

ProQR Therapeutics N.V. - Ordinary Shares (PRQR): $0.89

0.03 (+3.50%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add PRQR to Watchlist
Sign Up

Industry: Biotech


Ranked

of 402

in industry

Filter PRQR News Items

PRQR News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

PRQR News Highlights

  • For PRQR, its 30 day story count is now at 10.
  • Over the past 22 days, the trend for PRQR's stories per day has been choppy and unclear. It has oscillated between 1 and 3.
  • The most mentioned tickers in articles about PRQR are BEAT, DRUG and EYE.

Latest PRQR News From Around the Web

Below are the latest news stories about ProQR Therapeutics NV that investors may wish to consider to help them evaluate PRQR as an investment opportunity.

ProQR (PRQR) Reports Q4 Loss, Misses Revenue Estimates

ProQR (PRQR) delivered earnings and revenue surprises of -15.38% and 69.50%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Yahoo | February 24, 2022

ProQR Announces Fourth Quarter and Full Year 2021 Operating and Financial Results

Additional analyses ongoing from Phase 2/3 Illuminate trial of sepofarsen in LCA10 with updates on any potential next steps with this program and overall strategy anticipated in Q2 2022Phase 2/3 Sirius and Celeste clinical trials of ultevursen (QR-421a) in Usher syndrome and retinitis pigmentosa underway; interim data readout from Helia extension study of ultevursen planned by year-end 2022Repeated dose study planned for QR-1123 for autosomal dominant retinitis pigmentosa and initial data from m

Yahoo | February 24, 2022

Will ProQR (PRQR) Report Negative Q4 Earnings? What You Should Know

ProQR (PRQR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Yahoo | February 17, 2022

Why ProQR Therapeutics Stock Got Slammed Again Monday

Analysts are notably more bearish on the company following unhappy news about its leading drug candidate.

Yahoo | February 14, 2022

ProQR (PRQR) Plunges as Lead Drug Fails in Phase II/III Study

ProQR (PRQR) lead candidate sepofarsen did not meet primary and secondary goals in phase II/III study.

Yahoo | February 14, 2022

Why ProQR Therapeutics Is Crashing Today

Sepofarsen's failure to meet efficacy endpoints in the Illuminate trial isn't sitting well with investors.

Yahoo | February 11, 2022

ProQR Announces Top-Line Results from Phase 2/3 Illuminate Trial of Sepofarsen in CEP290-mediated LCA10

Study did not meet primary endpoint nor notable secondary endpoints – no benefit observed in either treatment arm versus shamAdditional analyses to be conducted and presented at a future medical congressSepofarsen continues to be generally well toleratedStrong cash position provides runway into mid- to late-2024ProQR Management to host conference call today at 8:15am EST LEIDEN, Netherlands & CAMBRIDGE, Mass., Feb. 11, 2022 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company

Yahoo | February 11, 2022

Raymond James’ 2 Stock Picks With Over 70% Upside Potential

What can it all mean when mega-cap stocks and US Treasuries start behaving as if they were penny stocks? Tavis McCourt, Institutional Equity Strategist at Raymond James, has an idea about that. “We would argue it shows a complete lack of conviction by investors in certain business models/earnings power, and the state of the economy overall,” McCourt wrote. McCourt is talking of the spell of extreme volatility the markets are currently going through, noting that investors can’t make up their mind

Yahoo | February 11, 2022

ProQR to Present at Upcoming SVB Leerink Conference

LEIDEN, Netherlands & CAMBRIDGE, Mass., Feb. 07, 2022 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a company dedicated to changing lives through the creation of transformative RNA therapies for genetic eye diseases, today announced that Company management will present at the upcoming virtual SVB Leerink 11th Annual Global Healthcare Conference. The presentation will be webcast live on February 17, 2022 from 1:40 – 2:05pm EST. Presentation and webcast details will b

Yahoo | February 7, 2022

Strength Seen in ProQR (PRQR): Can Its 7% Jump Turn into More Strength?

ProQR (PRQR) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Yahoo | February 2, 2022


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.5055 seconds.